Contents

Glossary

• 1.7.1.5 Appendix A - Blood Products
• 1.7.1.8 Gazettal of 'No Change' Scheduling Recommendations
• 1.8 NDPSC working parties
  • 1.8.1 Trans-Tasman Harmonisation Working Party
    • 1.8.1.2.2 Aciclovir
    • 1.8.1.2.3 Hyoscine butylbromide
    • 1.8.1.2.4 Juniperus sabine/savin oil
    • 1.8.1.2.5 Nicotine in NRT
    • 1.8.1.2.6 Alclometasone and clobetasone
    • 1.8.1.2.7 Hyoscine and hyoscyamine
    • 1.8.1.2.8 Paracetamol 665 mg
    • 1.8.1.2.9 Ibuprofen
    • 1.8.1.3.1 Strychnos spp
    • 1.8.1.4 Outcomes from TTHWP 13th Meeting

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.2 SUSDP, Part 2
  • 2.2.1 Labels for Schedule 8 substances
  • 2.2.2 Containers for essential oils

Top of page

Agricultural/Veterinary, Industrial and Domestic Chemicals

4. Other outstanding matters from previous meetings

• 4.1 Eyelash and eyebrow tinting products
• 4.2 Pyraflufen ethyl
• 4.3 Sodium hydroxide
• 4.4 Pine oils

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

• 6.1 Alpha-amylase / beta-gluconase / cellulase / pectinase / phytase / fungal protease / xylanase
• 6.2 Fipronil and 4-[4(acetyloxy)phenyl]-2-butanone (cue lure)
• 6.3 Potassium peroxomonosulfate/silver/ copper/sodium persulfate
• 6.4 Thiabendazole
• 6.5 Deracoxib
• 6.6 Forchlorfenuron

7. Matters referred by Office of Chemical Safety (OCS) branch

• 7.1 Glycolic acid

9. Other matters for consideration

• 9.1 Carbamide peroxide

Top of page

Pharmaceuticals

12. Matters arising from the minutes of the previous meeting (consideration of post-meeting submissions under 42ZCZ)

• 12.1 Aspirin
• 12.2 Ketamine

13. Other outstanding matters from previous meetings

• 13.1 Pseudoephedrine
• 13.2 Aripiprazole
• 13.3 Melia azedarach
• 13.4 Rosuvastatin
• 13.6 Zinc compounds
• 13.7 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) / 2,5-dimethoxy-4-iodophenethylamine (2C-I) / 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) / 5-methoxy-a-methyltryptamine (5-MEO-AMT)
• 13.8 Ibuprofen

14. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 14.1 SUSDP, Part 4
  • 14.1.1 Oseltamivir
  • 14.1.2 Diphenhydramine
  • 14.1.3 Diclofenac
• 14.2 SUSDP, Part 5
  • 14.2.1 Appendix H
    • 14.2.1.1 Orlistat
  • 14.2.2 Required advisory statements for medicine labels

15. Matters referred by the Australian Drug Evaluation Committee (ADEC)

• 15.1 New substances
  • 15.1.1 Moxonidine
  • 15.1.2 Efalizumab
  • 15.1.4 Emtricitabine

23. Amendments to the SUSDP

• 23.1 Editorial changes and errata
  • 23.1.1 Hyoscyamus niger
  • 23.1.2 Selenium
  • 23.1.3 Aspirin - for information